Drug · CHEMBL803

CYTARABINE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. CYTARABINE. Drugs and targets, record CHEMBL803. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL803

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: CYTARABINE; ChEMBL
ChEMBL ID: CHEMBL803; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Alexan, Alexan 100, Cytarabine component of vyxeos, Cytosar, Cytosar-u, Depocyt, Depocyte, Tarabine pfs; ChEMBL
Other names: Ara-c, Ara-cytidine, Arabinocytosine, Arabinosyl cytosine, Aracytidine, Aracytin, Aracytine, Citarabina, Cytarabine liposome, Cytarabinoside, Cytarabinum, NSC-287459, Spongocytidine, U 19920a, U-19,920, U-19920; ChEMBL
Other form: CYTARABINE HYDROCHLORIDE, CHEMBL1256472; Drugs and targets
DrugBank: DB00987; DrugBank
InChIKey: UHDGCWIWMRVCDJ-CCXZUQQUSA-N; ChEMBL
Open Targets' highest stage: Approval, for 6 of its 92 diseases, from ATC, ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA and PMDA; Open Targets

Targets11

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
POLA1	DNA polymerase (alpha/delta/epsilon)	DNA polymerase (alpha/delta/epsilon) inhibitor	INHIBITOR	https://conductscience.org/library/genes/5422
POLA2	DNA polymerase (alpha/delta/epsilon)	DNA polymerase (alpha/delta/epsilon) inhibitor	INHIBITOR	https://conductscience.org/library/genes/23649
POLD1	DNA polymerase (alpha/delta/epsilon)	DNA polymerase (alpha/delta/epsilon) inhibitor	INHIBITOR	https://conductscience.org/library/genes/5424
POLD2	DNA polymerase (alpha/delta/epsilon)	DNA polymerase (alpha/delta/epsilon) inhibitor	INHIBITOR	https://conductscience.org/library/genes/5425
POLD3	DNA polymerase (alpha/delta/epsilon)	DNA polymerase (alpha/delta/epsilon) inhibitor	INHIBITOR	https://conductscience.org/library/genes/10714
POLD4	DNA polymerase (alpha/delta/epsilon)	DNA polymerase (alpha/delta/epsilon) inhibitor	INHIBITOR	https://conductscience.org/library/genes/57804
POLE	DNA polymerase (alpha/delta/epsilon)	DNA polymerase (alpha/delta/epsilon) inhibitor	INHIBITOR	https://conductscience.org/library/genes/5426
POLE2	DNA polymerase (alpha/delta/epsilon)	DNA polymerase (alpha/delta/epsilon) inhibitor	INHIBITOR	https://conductscience.org/library/genes/5427
POLE3	DNA polymerase (alpha/delta/epsilon)	DNA polymerase (alpha/delta/epsilon) inhibitor	INHIBITOR	https://conductscience.org/library/genes/54107
PRIM1	DNA polymerase (alpha/delta/epsilon)	DNA polymerase (alpha/delta/epsilon) inhibitor	INHIBITOR	https://conductscience.org/library/genes/5557

1 to 10 of 11Source ChEMBL

See all 11 targets

Diseases92

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
acute myeloid leukemia	Approval	ClinicalTrials.gov, EMA Human Drugs, FDA and PMDA	662	659	https://conductscience.org/library/drugs?q=MONDO_0018874
acute lymphoblastic leukemia	Approval	DailyMed	227	216	https://conductscience.org/library/drugs?q=MONDO_0004967
myelodysplastic syndrome	Phase 3	ClinicalTrials.gov	158	157	https://conductscience.org/library/drugs?q=MONDO_0018881
non-Hodgkin lymphoma	Phase 3	ClinicalTrials.gov	83	83	https://conductscience.org/library/drugs?q=MONDO_0018908
chronic myeloid leukemia	Phase 3	ClinicalTrials.gov	39	39	https://conductscience.org/library/drugs?q=MONDO_0011996
mantle cell lymphoma	Phase 3	ClinicalTrials.gov	39	39	https://conductscience.org/library/drugs?q=MONDO_0018876
diffuse large B-cell lymphoma	Phase 3	ClinicalTrials.gov	36	36	https://conductscience.org/library/drugs?q=MONDO_0018905
lymphoblastic lymphoma	Phase 3	ClinicalTrials.gov	36	36	https://conductscience.org/library/drugs?q=MONDO_0000873
leukemia	Phase 3	ClinicalTrials.gov	34	34	https://conductscience.org/library/drugs?q=MONDO_0005059
Hodgkins lymphoma	Phase 3	ClinicalTrials.gov	30	30	https://conductscience.org/library/drugs?q=MONDO_0004952

1 to 10 of 92Source Open Targets

See all 92 diseases

Trials1,248

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 20 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 45 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT01190930	Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma	Phase 3	9,350	2020-06-23	cytarabine	Its name	ClinicalTrials.gov
NCT02883049	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations	Phase 3	5,949	2024-03-12	cytarabine	Its name	ClinicalTrials.gov
NCT00103285	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	Phase 3	5,377	2018-07-11	cytarabine	Its name	ClinicalTrials.gov
NCT00075725	Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia	Phase 3	3,154	2015-08-06	cytarabine	Its name	ClinicalTrials.gov
NCT00408005	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma	Phase 3	1,895	2019-06-20	cytarabine	Its name	ClinicalTrials.gov
NCT00025259	Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease	Phase 3	1,734	2017-03-07	cytarabine	Its name	ClinicalTrials.gov
NCT01371981	Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	Phase 3	1,645	2020-07-07	cytarabine	Its name	ClinicalTrials.gov
NCT00333840	Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia	Phase 3	1,106	2013-10-14	cytarabine	Its name	ClinicalTrials.gov
NCT00078949	Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma	Phase 3	849	2014-10-21	cytarabine	Its name	ClinicalTrials.gov
NCT01802333	Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia	Phase 3	754	2018-12-19	cytarabine	Its name	ClinicalTrials.gov

1 to 10 of 1,248

See all 1,248 trials

Comparisons in its trials210

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
All Patients for Induction, MRD Negative vs All Patients for Induction, MRD Positive: Early Marrow Status (EMS) by MRD Status End Induction (Day 29)	4,378 of 4,609	258 of 362	4,971	NCT00103285	Trial comparisons
Imatinib (STI571) vs IFN-a + Ara-C: Number of Participants With Serious Adverse Events as a Measure of Safety (First-line Treatment)	226 of 551	163 of 533	1,084	NCT00333840	Trial comparisons
Group A (Vosaroxin/Cytarabine) vs Group B (Placebo/Cytarabine): deaths from any cause	273 of 355	288 of 350	705	NCT01191801	Trial comparisons
Group A (Vosaroxin/Cytarabine) vs Group B (Placebo/Cytarabine): serious adverse events	197 of 355	125 of 350	705	NCT01191801	Trial comparisons
Thalidomide vs No Thalidomide: serious adverse events	323 of 323	345 of 345	668	NCT00083551	Trial comparisons
Placebo + Low-dose Cytarabine vs Volasertib + Low-dose Cytarabine: Objective Response (OR)	38 of 222	123 of 444	666	NCT01721876	Trial comparisons
Subjects Assigned to Placebo + Low-dose Cytarabine vs Subjects Assigned to Volasertib + Low-dose Cytarabine: deaths from any cause	40 of 222	138 of 439	661	NCT01721876	Trial comparisons
Subjects Assigned to Placebo + Low-dose Cytarabine vs Subjects Assigned to Volasertib + Low-dose Cytarabine: serious adverse events	163 of 222	380 of 439	661	NCT01721876	Trial comparisons
Standard Daunorubicin (Induction Therapy) vs High Dose Daunorubicin (Induction Therapy): serious adverse events	328 of 328	325 of 325	653	NCT00049517	Trial comparisons
Ara-C+Daunomycin vs Ara-C+Daunomycin+Mylotarg: Complete Remission	203 of 296	207 of 300	596	NCT00085709	Trial comparisons

1 to 10 of 210

See all 210 comparisons in its trials

Papers from its trials898

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40238563	RESULT	1	PubMed
39919267	RESULT	1	PubMed
37883081	RESULT	1	PubMed
36344419	RESULT	1	PubMed
35274287	RESULT	1	PubMed
35271306	RESULT	1	PubMed
34895843	RESULT	1	PubMed
34804017	RESULT	1	PubMed
34455741	RESULT	1	PubMed
33832208	RESULT	1	PubMed

1 to 10 of 898

See all 898 papers from its trials

Tests in its trials6

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	Source
Trail Making Test A	2	ConductCognition
Trail Making Test B	2	ConductCognition
Verbal Fluency	2	ConductCognition
Verbal Learning	2	ConductCognition
Complex Figure Copy and Recall	1	ConductCognition
Digit Span Test	1	ConductCognition

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL803

GET https://conductscience.org/api/drugs/v1/CHEMBL803/diseases?page=2

API reference For AI assistants